Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of RSS0393 Ointment in Healthy and Psoriatic Subjects
NCT06308393Phase 1Active, not recruiting
- Sponsor
- Hengrui
- Start
- Mar 2024
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of RSS0393 in psoriasis (3 arms), sponsored by Hengrui. Primary endpoints: The percent of Local skin tolerance was assessed as moderate or higher at Day 8 and Measurement of blood, urine, blood chemistry, and coagulation function examination at Day 42. Started Mar 2024; status: active, not recruiting.
02
Drugs
RSS0393
03
Conditions
psoriasis
Beyond the preview
Go deeper on NCT06308393.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06308393.